前收市價 | 33.22 |
開市 | 33.56 |
買盤 | 33.93 x 300 |
賣出價 | 33.99 x 100 |
今日波幅 | 32.80 - 34.19 |
52 週波幅 | 16.95 - 49.50 |
成交量 | |
平均成交量 | 1,379,955 |
市值 | 2.773B |
Beta 值 (5 年,每月) | 1.80 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.72 |
業績公佈日 | 2024年5月08日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 50.08 |
Beam stock launched a year-high Tuesday as enthusiasm grows for its next-generation form of gene editing, a rival to CRISPR.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. The Cambridge, Mass.-biotech company reported strong Q4 and full year 2023 results and reiterated milestones across the company's sickle cell disease and genetic disease portfolios. Check out "Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug."
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.